Table 3.
Changes in study variables (means ± standard deviation) between baseline and 48th week in patients receiving rosiglitazone, metformin, and no hypoglycemic treatment
| Variable | Treatment with rosiglitazone (n = 30) | P rosiglitazone/metformin* | Treatment with metformin (n = 30) | control (n = 30) | P* control/rosiglitazone | P* control/metformin |
|---|---|---|---|---|---|---|
| Fasting glucose (mmol/L): |
||||||
| baseline (t = 0) |
6.5 ± 0.20 |
0.156 |
6.6 ± 0.18 |
6.5 ± 0.21 |
1.000 |
0.156 |
| week 48 |
4.6 ± 0.34 |
0.015 |
4.4 ± 0.23 |
6.5 ± 0.19 |
<0.001 |
<0.001 |
|
P* |
<0.001 |
<0.001 |
0.971 |
|||
| Fasting insulin (mIU/l): |
||||||
| baseline (t = 0) |
39.0 ± 3.35 |
0.663 |
40.3 ± 2.29 |
39.0 ± 3.54 |
1.000 |
0.663 |
| week 48 |
19.7 ± 3.99 |
<0.001 |
29.2 ± 2.82 |
39.7 ± 3.35 |
<0.001 |
<0.001 |
|
P* |
<0.001 |
<0.001 |
0.962 |
|||
| Beta cell function: |
||||||
| baseline (t = 0) |
261.3 ± 28.0 |
1.000 |
257.3 ± 21.9 |
261.3 ± 28.8 |
1.000 |
1.000 |
| week 48 |
403.3 ± 162.5 |
<0.001 |
707.4 ± 207.3 |
261.7 ± 26.7 |
<0.001 |
<0.001 |
|
P* |
<0.001 |
<0.001 |
1.000 |
|||
| Insulin resistance: |
||||||
| baseline (t = 0) |
11.3 ± 1.03 |
0.102 |
11.9 ± 0.73 |
11.3 ± 1.10 |
1.000 |
0.103 |
| week 48 |
4.0 ± 0.95 |
<0.001 |
5.7 ± 0.62 |
11.6 ± 1.06 |
<0.001 |
<0.001 |
| P* | <0.001 | <0.001 | 0.845 | |||
*Repeated measures ANOVA (Post hoc Tukey HSD test).